Company type
Limited Corporation (APS)
Established
2006
Size
Micro
Employees
9
Revenue
- DKK
Gross profit
30 MDKK
Operating Profit (EBIT)
22 MDKK
Profit for the year
16 MDKK
Equity
52 MDKK
ad

More financial key figures and analyses?

In Bisbase Premium you get more financial key figures for both companies, groups and industries plus access to exclusive industries complied by experts. You can also create your own analyses! It only takes a minute or so - and it's free!

Rank Profit for the year

Rank in industry
1/31
"Top 10%"
Rank in Denmark
7,884/347,086
"Top 10%"

Top management top 3

Legal owners top 3

Rights certificate

Selskabet tegnes af direktøren

Company information based on CVR

NamePharma Medico Aps
Alternate namesPharma Medico Group Aps, Pharma Medico International Aps, Pharma Medico Us Aps Show more
CVR28665741
AddressHans Hartvig Seedorffs Stræde 12, 8000 Aarhus C
IndustryManufacture of basic pharmaceutical products [211000]
Webwww.pharmamedico.com
Established04-07-2006 (17 yr)
First financial statement period04-07-2006 to 31-12-2007
Company typeLimited Corporation (APS)
Number of employees12 (man years:9)
Advertising protectionYes
AuditorDeloitte Statsautoriseret Revisionspartnerselskab since 13-10-2011
Financial statement period01-01 to 31-12
Company capital126,250 DKK
125,000 DKK (04-07-2006 - 27-12-2016)
Articles of assoc. last30-05-2017

Member of industries

Purpose

Selskabets formål er at forske i, udvikle, producere og markedsføre fødevarer, kosmetik og farmaceutiske produkter samt anden dertil knyttet virksomhed efter ledelsens nærmere bestemmelse. Selskabet tilstræber at drive sin virksomhed på økonomisk, miljømæssigt og socialt ansvarlig vis.

Financial Statement

 202220212020
Currency/unit000' DKK000' DKK000' DKK
Revenue
-
-
-
-
-
-
Gross Profit
30,301
+58%
19,238
+80%
10,687
-22%
Profit for the year
16,438
+58%
10,383
+427%
1,969
-59%
Equity
51,511
+30%
39,573
+36%
29,190
+7%
Total Assets
63,767
+32%
48,216
+33%
36,267
+6%

Mangement review

Udvikling i aktiviteter og økonomiske forholdSelskabet har i 2022 fortsat sine investeringer i brand positionering, klinisk dokumentation og generel markedsføring. Ud over det normale investerings niveau er der foretaget signifikante investeringer i digitale platforme og applikationer.

Selskabets resultat anses for værende tilfredsstillende.
19-06-2023

Map